harpoontx.com - הכנסה לפני ניכוי ריבית, מסים ופחת HARP

Harpoon Therapeutics develops cancer treatment methods via the TriTAC platform. The automation of antibody synthesis in laboratories accelerates drug release. Absolute operating profit reflects current cash flow dynamics, where represents the latest level value. The business valuation currently depends not on sales, but on the prospects of selling unique technologies through M&A transactions.

This metric reflects net cash flow from operating activities, excluding depreciation and accounting adjustments to assess real operational efficiency. By analyzing EBITDA, an investor can discern the business resilience of Harpoon Therapeutics (HARP) amid geopolitical barriers, which directly impact operating expense dynamics through biomaterial logistics disruptions and drug certification delays.